FLU WARS: Egg-free Flublok, quad vax backed for 2013-14 arsenal
This article was originally published in Scrip
Executive Summary
As the US heads into 2013-14 influenza season this fall, among the new vaccines health care providers will have for the first time in their arsenal of weapons to fight the virus will be Protein Sciences' trivalent recombinant hemagglutinin vaccine Flublok, which won the backing of a panel of advisers to the US Centers for Disease Control and Prevention (CDC) on 20 June as the product of choice for adults allergic to eggs.